Correlation Between Levels of 25-Hydroxy-Vitamin D and Degree of Anemia in Patients with Chronic Kidney Disease
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 4, July 2017, Pages: 151-156
Received: May 16, 2017; Accepted: May 27, 2017; Published: Jul. 18, 2017
Views 1827      Downloads 84
Authors
Elena López-Ramiro, Biochemistry Laboratory, Sanitary Research Institute Jiménez Díaz Foundation, Madrid, Spain
Mercedes Rubert, Biochemistry Laboratory, Sanitary Research Institute Jiménez Díaz Foundation, Madrid, Spain
Emilio González-Parra, Nefrology, Sanitary Research Institute Jiménez Díaz Foundation, Madrid, Spain
Ignacio Mahillo, Epidemiology and Statistics, Sanitary Research Institute Jiménez Díaz Foundation, Madrid, Spain
Concepción de la Piedra, Biochemistry Laboratory, Sanitary Research Institute Jiménez Díaz Foundation, Madrid, Spain
Article Tools
Follow on us
Abstract
Introduction: Vitamin D exercises pleiotropic effects independently of calcium and phosphorous homeostasis. Purpose: To analyze the possible correlation between levels of 25-hydroxy vitamin D (25(OH)D) and other parameters of patients with chronic kidney disease (CKD). Patients and methods: One hundred and forty-five patients with stage-5 CKD were studied (mean age 65.9 ± 14.6 years; 74 males and 71 females; Levels of 25(OH)D, age, bone alkaline phosphatase, procollagen I amino-terminal propeptide, carboxyterminal telopeptide of collagen I, intact parathyroid hormone (PTH), bio-PTH, hemoglobin, hematocrit, urea, creatinine, total proteins, albumin, iron, iron saturation index, calcium, phosphorous, total alkaline phosphatase, serum CO2, cholesterol, triglycerides, C-reactive protein, prealbumin, ferritin, proBNP, and fibroblast growth factor-23 (FGF-23) were determined. Spearman’s correlation coefficient and p values were analyzed. Results: This work show a positive correlation between levels of 25(OH)D and anemia (i.e., hemoglobin, hematocrit, iron, iron saturation index, and ferritin). Conclusion: These results show the close relationship between the degree of anemia in patients with CKD and 25(OH)D levels. It is of great importance to maintain levels of 25(OH)D in patients with advanced-stage CKD, as this can decrease anemia levels and, in turn, lower quantities of erythropoietin would be necessary to maintain hematocrit.
Keywords
Hemodialysis Patients, 25(OH) Vitamin D, Anemia
To cite this article
Elena López-Ramiro, Mercedes Rubert, Emilio González-Parra, Ignacio Mahillo, Concepción de la Piedra, Correlation Between Levels of 25-Hydroxy-Vitamin D and Degree of Anemia in Patients with Chronic Kidney Disease, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 4, 2017, pp. 151-156. doi: 10.11648/j.ajcem.20170504.18
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Rojas Rivera J, De la Piedra C, Ramos A, Ortiz A, Egido J. The spanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: 2850-2865.
[2]
Melamed ML, Michos ED, Post W, Astor B. Calcifediol levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
[3]
Clayton P, Singer R. 25- Hydroxyvitamin D levels in prevalent Australian dialysis patients. Nephrology 2009; 14: 554-559.
[4]
Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
[5]
Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-15.
[6]
Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1–S130.
[7]
Dusso A, Tokumoto M: Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: 715–729.
[8]
Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nemeth Z, Szabo A, Mucsi I. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and eritropoyetin resistance in patients on maintenance hemodialysis. Nephron Clin Prac 2011; 117: c373-c378.
[9]
Ertürk S, Kutlai S, Karabulut HG, Keven K, Nergizoglu G, Ates K, Bokesoy I, Duman N. The impact of vitaminD receptor genotype on the management of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 816-823.
[10]
Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D deficiency and effects of supplementation with ergocalciferol in stage 5 chronic kidney disease patients. J Ren Nutr 2008; 18: 375-382.
[11]
Naini AE, Hedaiati ZP, Gholami D, Pezeshki AH, Moinzadeh F. The effect of vitamin D administration on treatment of anemia in end-stage renal disease patients with vitamin D deficiency on hemodialysis: a placebo-controlled double-blind clinical trial. J Res Med Sci 2015; 20: 745-750.
[12]
Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol 2011; 24: 98-115.
[13]
Patel NM, Gutierrez OM, Andress DL, Coyne DW, Levin A, Wolf M. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney International 2010; 77: 715-720.
[14]
Rianthavorn P, Boonyapapong P. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr Nephrol 2013; 28: 1261-1266.
[15]
Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M et al. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS One 2015; 10: e0118174.
[16]
Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Ruso R, Cozzolino M. Renal anemia and EPO hiporesponsiveness associated with vitamin D deficiency: the potential role of in inflammation. Nephrol Dial Transplant 2013; 28: 1672-1679.
[17]
Davis SL, Litlewood TJ. The investigation and treatment of secondary anemia. Blood Rev 2012; 26: 65-71.
[18]
Kendrick J, Targher G, Smits G, Chonchol M. 25-hydroxyvitaminD deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 2009; 30: 64-72.
[19]
Nagaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268.
[20]
Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N EnglJ Med 1989; 320: 980-991.
[21]
Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-5548.
[22]
Sim J, Lac PT, Liu ILA, Megerditchian SO, Kumar V, Kujubu DA Rasgon SA. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010; 89: 447-452.
[23]
Lac PT, Choi K, Liu IA, Meguerditchian S, Rasgon SA, Sim JJ. The effects of changing vitamin D levels on anemia in chronic kidney disease patients: a retrospective cohort review. Clinical Nephrology 2010; 74: 25-32.
[24]
Babit JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741.
[25]
Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15: S21-S24.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186